A reagent resource to identify proteins and peptides of interest for the cancer community
2006 (English)In: Molecular and Cellular Proteomics, ISSN 1535-9476, Vol. 5, no 10, 1996-2007 p.Article in journal (Refereed) Published
On the basis of discussions with representatives from all sectors of the cancer research community, the National Cancer Institute (NCI) recognizes the immense opportunities to apply proteomics technologies to further cancer research. Validated and well characterized affinity capture reagents (e.g. antibodies, aptamers, and affibodies) will play a key role in proteomics research platforms for the prevention, early detection, treatment, and monitoring of cancer. To discuss ways to develop new resources and optimize current opportunities in this area, the NCI convened the "Proteomic Technologies Reagents Resource Workshop" in Chicago, IL on December 12-13, 2005. The workshop brought together leading scientists in proteomics research to discuss model systems for evaluating and delivering resources for reagents to support MS and affinity capture platforms. Speakers discussed issues and identified action items related to an overall vision for and proposed models for a shared proteomics reagents resource, applications of affinity capture methods in cancer research, quality control and validation of affinity capture reagents, considerations for target selection, and construction of a reagents database. The meeting also featured presentations and discussion from leading private sector investigators on state-of-the-art technologies and capabilities to meet the user community's needs. This workshop was developed as a component of the NCI's Clinical Proteomics Technologies Initiative for Cancer, a coordinated initiative that includes the establishment of reagent resources for the scientific community. This workshop report explores various approaches to develop a framework that will most effectively fulfill the needs of the NCI and the cancer research community.
Place, publisher, year, edition, pages
2006. Vol. 5, no 10, 1996-2007 p.
antibody, biological marker, reagent, biomedical technology assessment, cancer research, conference paper, data base, health care organization, high throughput screening, human, mass spectrometry, nonhuman, priority journal, process development, protein analysis, proteomics, quality control, reproducibility, validation process, workshop, Biomedical Research, Humans, Indicators and Reagents, Neoplasm Proteins, Neoplasms, Peptides, Protein Biosynthesis, Reproducibility of Results
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
IdentifiersURN: urn:nbn:se:kth:diva-155985DOI: 10.1074/mcp.T600020-MCP200ISI: 000241519300026ScopusID: 2-s2.0-33750617917OAI: oai:DiVA.org:kth-155985DiVA: diva2:765878
QC 201411252014-11-252014-11-172015-10-14Bibliographically approved